Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue...
17 insider purchases on record · latest filing 2025-03-25.
Insiders have also filed 46 sale transactions at GLUE.